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and Reproductive Sciences, University of California, San Francisco, CaliforniaObjective: To evaluate the effectiveness of semen washing in human immunodeﬁciency virus (HIV)–discordant couples in which the
male partner is infected.
Design: Systematic review and meta-analysis.
Setting: Not applicable.
Patient(s): Forty single-arm open-label studies among HIV-discordant couples that underwent intrauterine insemination (IUI) or
in vitro fertilization (IVF) with or without intracytoplasmic sperm injection (ICSI) using washed semen.
Intervention(s): Semen washing followed by IUI, IVF, or IVF/ICSI.
Main OutcomeMeasure(s): Primary outcome: HIV transmission to HIV-uninfected women; secondary outcomes: HIV transmission to
newborns and proportion of couples achieving a clinical pregnancy.
Result(s): NoHIV transmissionoccurred in11,585cyclesof assisted reproductionwith theuseofwashed semenamong3,994women.Among
the subset of HIV-infectedmenwithout plasma viral suppression at the time of semenwashing, noHIV seroconversions occurred among 1,023
womenafter 2,863 cycles of assisted reproductionwith the use ofwashed semen. Studies thatmeasuredHIV transmission to infants reportedno
cases of vertical transmission. Overall, 56.3% of couples (2,357/4,184) achieved a clinical pregnancy with the use of washed semen.
Conclusion(s): Semen washing appears to signiﬁcantly reduce the risk of transmission in HIV-discordant couples desiring children,
regardless of viral suppression in the male partner. There are no randomized controlled studies or studies from low-income
countries, especially those with a large burden of HIV. Continued development of lower-cost semen washing and assisted
reproduction technologies is needed. Integration of semen washing into HIV prevention interventions could help to further reduce
the spread of HIV. (Fertil Steril 2016;105:645–55. 2016 The Authors. Published by Elsevier Inc. on behalf of the AmericanUse your smartphone
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A pproximately 37 million people are living with humanimmunodeﬁciency virus (HIV) worldwide (1) and>80% of HIV-infected individuals are of childbearing
age (2). A cornerstone of successful HIV prevention campaigns
has included the promotion of consistent condomuse (3). How-
ever, many heterosexual HIV-discordant couples desire preg-
nancy (4, 5), and consistent condom usage is incompatible
with that desire. Couples may risk sexual HIV transmission
to achieve pregnancy if they do not have access to safer
reproductive methods (4, 6, 7). Semen washing is a safer
reproductive strategy that HIV-discordant couples, in which
the male is infected, can use to achieve pregnancy (8).
Semen washing removes spermatozoa, which are not vec-
tors for HIV, from the surrounding seminal ﬂuid, and the HIV-
negative sperm fractions are used in assisted reproduction (8).
The ﬁrst study, from 1989, of semen washing for HIV-
discordant couples, with the use of intrauterine insemination
(IUI), found no HIV transmission to 29 uninfected female part-
ners (9). In the two decades following the introduction of semen
washing, many more studies have evaluated the effect of this
method in conjunctionwith assisted reproductive technologies,
such as IUI, in vitro fertilization (IVF), and IVF with intracyto-
plasmic sperm injection (ICSI), on HIV transmission in HIV-
discordant couples (10–12). We conducted a systematic
review andmeta-analysis of these studies to estimate the safety
and effectiveness of semen washing in reducing HIV transmis-
sion in HIV-discordant couples in which the male is infected.
Three systematic reviews addressing prevention of HIV
transmission in HIV-discordant couples after semen washing
have been completed to date. The ﬁrst, by Vitorino et al. (10),
included 17 observational studies published through
December 2007. The second review, by Eke et al. (11),
searched for randomized controlled trials published through
December 2010 but did not identify any. The third review,
by Savasi et al., included 22 observational studies through
May 2012 (12). Our systematic review expands on all three re-
views by including observational studies, studies of any size,
and studies published in any language through December
2014. Barnes et al. (13) published a related systematic review
in 2014 that reviewed 24 articles with the primary objective to
evaluate reproductive outcomes among HIV-affected couples
after IUI and IVF, speciﬁcally fecundability, miscarriage rates,
andmultiple gestation rates. Our systematic review andmeta-
analysis complements the review by Barnes et al. (13) by eval-
uating the effectiveness of semen washing in reducing HIV
transmission in HIV-discordant couples.
ORIGINAL ARTICLE: ANDROLOGYMATERIALS AND METHODS
With the use of Cochrane Collaboration methods, we con-
ducted a rigorous systematic review and meta-analysis. We
assessed evidence quality with the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
methodology (14). We reported our ﬁndings in accordance
with Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines (15).
We developed a search strategy to identify studies with
abstracts published through December 2014 in four major
electronic databases—Medline (via Pubmed), Cochrane646Library, Scopus, and the World Health Organization's
(WHO) Global Index Medicus. We also searched the Interna-
tional AIDS Conference, British HIV Association Conference,
International Conference of Obstetricians and Gynecologists,
American Academy of HIV Medicine Conference, American
Society for Reproductive Medicine Conference, European So-
ciety for Hum Reprod and Embryology Conference, and
British Fertility Society Conference for relevant abstracts. In
addition to National Library of Medicine Medical Subject
Heading (MeSH) terms and other specialized syntax, our
search strategies used key terms related to ‘‘sperm washing,’’
‘‘assisted reproduction,’’ and ‘‘HIV.’’ We also hand searched
the references of existing reviews and studies on semen
washing. We considered articles regardless of year of publica-
tion, language, or sample size.
The inclusion criteria for studies were: 1) studies that eval-
uated semen washing; 2) comparative and noncomparative
observational and experimental studies, such as clinical trials,
cohort studies, and pre-post studies; 3) studies among HIV-
discordant couples in which the male was infected and the
female partner was attempting pregnancy; and 4) studies that
reported the HIV status of the female partner before and after
she underwent assisted reproduction with semen washing. Pri-
mary outcomes were serologic evidence of HIV infection in fe-
male partners after semen washing and virologic evidence of
HIV infection innewborns following birth.We excluded studies
that did notmeasureHIV status of the female partner before and
after insemination with washed semen. Secondary outcomes
included the proportion of women who achieved clinical preg-
nancy, the proportion of women who had spontaneous abor-
tions/miscarriages, the proportion of infants born with low
birth weight, and the proportion of deliveries that were prema-
ture. This review followed the ‘‘best available evidence
approach’’ (16) and included single-group open-label studies
that evaluated all subjects before and after undergoing a single
intervention. Although studies using a randomized blinded
control group are considered to be the highest quality, the
best available evidence approach can be taken when those
studies are not available (16).
Two authors (M.Z. and J.B.) independently screened ab-
stracts gathered from electronic database and hand searches.
After discussion on discrepancies about abstract inclusion,
the authors selected a list of articles for full text review.
They independently extracted the following data from
included studies and compiled them into prepiloted data ta-
bles: 1) study details, including design, period of recruitment,
setting, number of couples enrolled, eligibility criteria,
method of semen washing and testing, and post-wash semen
positivity; 2) time point for HIV testing of women and infants
and the number of HIV seroconversions among both groups;
3) other clinical data, including viral loads and CD4 cell
counts of male patients and the proportion of male patients
on antiretroviral therapy; 4) assisted reproductive techniques
used (IUI, IVF, or IVF/ICSI); and 5) reproductive outcomes,
including pregnancy, spontaneous abortions, low birth
weight, and premature deliveries.
Our systematic review and meta-analysis did not involve
human subjects and therefore did not require Institutional Re-
view Board approval.VOL. 105 NO. 3 / MARCH 2016
Fertility and Sterility®Statistical Analysis
We pooled data from the studies to derive an estimate of the
total reported number of couples who have used semen
washing, the total number of semen washing cycles that
have been performed, and the total reported number of in-
fants born among couples using this method. We calculated
the 95% conﬁdence intervals (CIs) of HIV transmission risk
per cycle and per couple for this pooled estimate according
to the Jeffreys method (17). We used a one-sided exact bino-
mial test to assess whether the overall probabilities of HIV
transmission per cycle and per couple were lower than the his-
torical estimate of per-coital probability of HIV transmission,
which is 0.1% (18, 19).
We calculated the proportion of women who acquired
HIV for each study and performed a proportion meta-
analysis with the use of the random-effects methods of DerSi-
monian and Laird (20). We tested for heterogeneity in effects
with the use of the I2 statistic.
We calculated the proportion of women achieving clinical
pregnancy by dividing the number of reported clinical preg-
nancies by the total number of cycles initiated, which
included cancelled and completed cycles (21). Not all studies
in this review reported pregnancy results, and studies that re-
ported pregnancy results did not always report results per
couple and per cycle. Moreover, not all studies reported preg-
nancy results disaggregated by type of assisted reproductive
procedure (e.g., IUI vs. IVF or IVF/ICSI). Therefore, numerators
and denominators for the pregnancy outcomes vary from the
numerators and denominators for the HIV outcomes and do
not consistently add up to the total number of events
observed.
We also conducted a subgroup analysis among those cou-
ples in which the HIV-infected male partner had not achieved
viral suppression (determined by plasma viral load) at the time
of semen washing. This analysis estimated the independent
effect of semen washing on HIV prevention in the absence
of viral suppression. The subgroup includedmen without viral
suppression regardless of antiretroviral use. When articles re-
ported the number of men without viral suppression, but not
the explicit number of cycles of assisted reproduction per-
formed on their partners, we estimated this number by
assuming that the subgroup underwent a similar number of
cycles as couples with viral suppression. The deﬁnition of
viral suppression used by authors of the included studies var-
ied over time from <50 to <400 copies/mL. In studies where
neither viral load nor use of antiretroviral medication was re-
ported, the authors contacted corresponding authors to
request this information.
We conducted all data analyses with the use of Stata soft-
ware version 12.0 (Statacorp).Assessing the Quality of Evidence
To comment on the overall quality of evidence, we assessed
the risk of bias in each study. This parameter was our main
consideration because it informs how conﬁdently we can
accept the results of studies. There is no single generic instru-
ment recommended for assessing bias risk in observational
studies (22). To determine the risk of bias in each study, weVOL. 105 NO. 3 / MARCH 2016adapted the GRADE Working Group (23) recommendations
to assess the following limitations of observational studies:
1) failure to develop and apply appropriate eligibility criteria;
2) ﬂawed measurement of both exposure and outcome; 3)
failure to adequately control confounding; and 4) incomplete
follow-up. GRADE is not typically used to assess evidence
quality of outcomes reported in single-arm studies; therefore,
we modiﬁed GRADE to evaluate evidence quality for HIV-
related outcomes in our review.RESULTS
Search Results
The electronic database and conference website searches
retrieved 249 relevant abstracts, and hand searching of previ-
ous systematic reviews and studies retrieved an additional six
abstracts (Fig. 1). Of these 255 abstracts, 12 were duplicates,
and after screening the remaining 243 we selected 47 for
full-text review. These articles were published in English (n
¼ 40), Hebrew (n ¼ 2), Portuguese (n ¼ 2), Dutch (n ¼ 1),
French (n ¼ 1), and Spanish (n ¼ 1). A total of 40 studies
(37 published articles and three conference abstracts) met
our eligibility criteria and were included in this review
(Table 1).
We found no randomized controlled trials. All included
studies were single-arm, open-label, pre-post test designs.
Eighteen studies were prospective, 21 were retrospective,
and one evaluated both retrospective and prospective cohorts.
All of the studies took place in high- and upper-middle-
income countries representing North American, European,
Asian, and Latin American regions.Population Studied
In the 40 included studies, a total of 4,257 HIV-discordant
couples completed 11,915 cycles of assisted reproduction af-
ter semen washing (Table 2). Men using assisted reproductive
services ranged in age from 29 to 58 years and women from
29 to 40 years (Supplemental Table 1, available online at
www.fertstert.org). The vast majority of women (93.8%,
3,994/4,257) and completed cycles (97.2%, 11,585/11,915)
had HIV test results available before and after exposure to
washed semen (Table 2).
Twenty-one studies reported antiretroviral use among
male participants; of the 2,326 men in those studies, 641
(27.6%) were not taking antiretrovirals at the time of semen
washing. Twenty-eight studies reported men's plasma viral
load; of the 1,890 men in those studies, 985 (52.1%) were
not virally suppressed at the time of semen washing. Overall,
a minimum of 24% of the couples (1,023/4,257) in the 40
studies were estimated to have not achieved viral suppres-
sion at the time of semen washing; this includes men
without viral suppression at the time of semen washing
(n ¼ 985) and men without a viral load measurement who
were known to not be taking antiretroviral medications
(n ¼ 38). Among the 21 studies that reported CD4 levels,
the average CD4 count of HIV-infected men ranged from
200 to 608 cells/mL.647
FIGURE 1
Article selection process with use of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines ﬂowchart.
Zafer. Semen washing and HIV prevention. Fertil Steril 2016.
ORIGINAL ARTICLE: ANDROLOGYSemen Washing Technique
Twenty-nine studies in this review reported washing semen
with the use of a technique invented by Semprini et al. in
1989 (8) (Table 1). Some studies used a polymerase chain reac-
tion (PCR) to detect HIV DNA and RNA in the washed semen
fractions (62). Five studies reported post-wash semen RNA pos-
itivity, ranging from 1.3% to 7.7% (24, 29, 36, 49, 60) (Table 1).
Seminal fractions that tested positive for HIV were discarded.HIV Transmission after Semen Washing
There were no cases of HIV transmission after exposure to
washed semen among 3,994 women undergoing 11,585 cy-
cles of assisted reproduction (0/11,585, 95% CI 0–0.0001).
This per-cycle HIV transmission risk is signiﬁcantly lower
(P< .001) than the historical HIV transmission risk estimate
of 0.1% per act of unprotected vaginal intercourse (18, 19).
Results of the meta-analysis are presented in Figure 2. Given
that there were no cases of HIV transmission in any study, the
I2 score was 0%, indicating no observed heterogeneity.648There were no HIV seroconversions among the subset of
1,023 couples in which the HIV-infected man was not virally
suppressed. Those couples underwent an estimated 2,863 cy-
cles of assisted reproduction involving IUI, IVF, and IVF/ICSI
(Table 2) and had an estimated per-cycle risk of HIV serocon-
version of 0 (0/2863, 95% CI 0–0.0006). This per-cycle HIV
transmission risk is signiﬁcantly lower (P¼ .05) than the his-
torical HIV transmission risk of 0.1% per act of unprotected
vaginal intercourse (18, 19).
In studies that provided data on mother-to-child HIV
transmission, there were no cases of vertical transmission
among 1,026 newborns, either at birth or at the follow-up
evaluations (0/1,026, 95% CI 0–0.0029).Pregnancy after SemenWashing with IUI, IVF, and
IVF/ICSI
Assisted reproduction techniques included IUI with ovarian
stimulation or natural cycles (10), IVF, and IVF/ICSI. In
studies that reported pregnancy outcomes per women, ofVOL. 105 NO. 3 / MARCH 2016
TABLE 1
Description of the 40 studies included in this review, with assisted reproduction technique and semen washing technique used.
Study Location
Period of
recruitment Study design
Couples
(n)
Assisted
reproduction
technique
Technique used in semen
preparation
Technique used
in post-wash
semen testing
Post-wash semen
positivity (%)
Semprini 1992 (9) Italy NR Single-arm open trial 29 IUI Density gradient and swim-up Monoclonal HIV
antibody
NR
Marina 1998 (24) Spain NR Single-arm open trial 63 IUI Density gradient and swim-up PCR, RT-PCR 5.6 (DNA)
Marina 1998 (25) Spain NR Case report 1 IVF  ICSI Density gradient and swim-up PCR, RT-PCR NR
Veiga 1999 (26) Spain 02/1997–12/1998 Single-arm open trial 75 IUI, IVF  ICSI Density gradient and swim-up PCR, RT-PCR NR
Loutradis 2001 (27) Greece 1999–2000 Case series 2 IVF  ICSI Density gradient and swim-up NR NR
Weigel 2001 (28) Germany 1991–1999 Retrospective chart review 54 IUI, IVF  ICSI Density gradient and swim-up PCR NR
Marina 2002 (29) Spain NR Single-arm open trial 273 IUI, IVF  ICSI Density gradient and swim-up PCR, RT-PCR 2.5 (DNA),
1.3 (RNA)
Quintana 2002 (30) Argentina NR Single-arm open trial 15 IUI, IVF  ICSI Density gradient PCR NR
Cleary-Goldman
2003 (31)
USA 01/1997–06/2002 Retrospective chart review 25 IVF  ICSI Double swim-up NR NR
Ohl 2003 (32) France 01/2001–07/2002 Single-arm open trial 39 IUI, IVF  ICSI Density gradient and swim-up PCR NR
Pena 2003 (33) USA 07/1997–07/2002 Retrospective chart review 58 IVF  ICSI Density gradient and swim-up NR NR
Pena 2003 (34) USA 08/1997–02/2002 Case series 5 IVF  ICSI – NR NR
Bujan 2004 (35) France 12/1999–12/2001 Single-arm open trial 56 IUI Density gradient and swim-up PCR, RT-PCR NR
Garrido 2004 (36) Spain 08/2001–10/2003 Retrospective chart review 51 IVF  ICSI Density gradient and swim-up Nested PCR, RT-PCR 7.7 (RNA),
2.6 (DNA)
Chu 2005 (37) USA 07/1997–04/2004 Retrospective chart review 92 IVF  ICSI Density gradient and swim-up PCR NR
Kowalska 2005 (38) Poland 05/2002–03/2005 Case series 13 IUI Density gradient and swim-up PCR, RT-PCR NR
Lowenstein
2005 (39)
Israel NR Single-arm open trial 2 IUI Density gradient RT-PCR NR
Mencaglia
2005 (40)
Italy 01/2001–12/2003 Single-arm open trial 25 IVF  ICSI Density gradient and swim-up NR NR
van Leeuwen
2005 (41)
Netherlands 2003–10/2004 Single-arm open trial 20 IUI Density gradient and swim-up RT-PCR NR
Chelo 2006 (42) Italy NR Single-arm open trial 49 IVF  ICSI Density gradient and swim-up RT-PCR NR
Chu 2006 (43) USA 08/1997–03/2004 Retrospective chart review 106 IVF  ICSI – NR NR
Kato 2006 (44) Japan NR Single-arm open trial 43 IVF  ICSI Density gradient and swim-up RT-nested PCR NR
Manigart 2006 (45) Belgium 01/2000–06/2005 Single-arm open trial 38 – Density gradient and swim-up RT-PCR NR
Bujan 2007 (46) Europe 1989–2003 Retrospective multicentre
study
1036 IUI, IVF  ICSI Density gradient & swim-up NR NR
Bujan 2007 (47) France 06/2000–08/2003 Retrospective chart review 84 IUI Density gradient and swim-up PCR, RT-PCR NR
Bujan 2007 (48) France 2004 Case report 1 IVF  ICSI Density gradient and swim-up RT-PCR NR
Savasi 2007 (49) Italy 01/2002–01/2006 Retrospective chart review 741 IUI, IVF  ICSI Density gradient & swim-up Real-time PCR 4.0 (RNA)
Queiroz 2008 (50) Brazil 06/2001–05/2007 Retrospective chart review 11 IVF  ICSI Density gradient RT-PCR NR
Pankam 2008 (51) Thailand 08/2006–12/2007 Single-arm open trial 43 IUI Density gradient and swim-up NR NR
Garrido 2009 (52) Spain 08/2007–11/2008 Case report 1 IVF  ICSI Density gradient PCR NR
Kashima 2009 (53) Japan 01/2001–07/2007 Single-arm open trial 26 IVF  ICSI Density gradient and swim-up Nested PCR NR
Sauer 2009 (54) USA 01/1998–12/2007 Retrospective chart review 181 IVF  ICSI Density gradient and swim-up PCR NR
Nicopollous
2010 (55)
UK 1999–2008 Retrospective chart review 259 IUI, IVF  ICSI Density gradient and swim-up PCR NR
Giles 2011 (56) Australia 2003–06/2010 Single-arm open trial 27 IUI, IVF  ICSI Density gradient PCR, RT-PCR NR
Schuffner 2011 (57) Brazil NR Case Report 10 IUI Density gradient and swim-up RT-PCR NR
Wu 2011 (58) Taiwan 2005–2009 Single-arm open trial 14 IVF  ICSI Density gradient and swim-up Real-time PCR NR
Zafer. Semen washing and HIV prevention. Fertil Steril 2016.
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ORIGINAL ARTICLE: ANDROLOGYthe 4,184 couples that initiated a cycle of reproduction, 2,357
(56.3%, 95% CI 54.8%–57.8%) had a clinical pregnancy
(Supplemental Table 1). Based on reported data, the propor-
tions of couples achieving pregnancy with the use of IUI
(56.4%, 95% CI 54.2%–58.5%) and IVF or IVF/ICSI (58.1%,
95% CI ¼ 55.0%–61.1%) were similar (P¼ .37). In studies
that reported pregnancy outcomes per cycle, 19.9% (95% CI
19.1%–20.6%) of initiated assisted reproduction cycles re-
sulted in a clinical pregnancy (Supplemental Table 1). In
studies that reported data on spontaneous abortions, 17.0%
(95% CI 15.4%–18.6%) of clinical pregnancies ended with a
spontaneous abortion. Rates of spontaneous abortions after
IUI (15.5%, 95% CI 13.4%–17.7%) and IVF or IVF/ICSI
(17.7%, 95% CI 13.9%–22.0%) were similar (P¼ .32).
Four studies reported birth weight and preterm delivery
outcomes (31, 34, 54, 61). Of 259 infants, 115 (44.4%) were
born with low (<2,500 g) or very low (<1,500 g) birth
weight and 107 (41.3%) were born prematurely (before
37 weeks of gestation). All of the women who experienced
premature delivery or gave birth to infants with low birth
weight had undergone IVF or IVF/ICSI. The rate of multiple
gestations among ongoing/delivered pregnancies was
43.5% (81/186).Quality of Evidence
All of the 40 included studies enrolled populations of HIV-
discordant couples that addressed the study question.
Thirty-nine studies were conducted in a controlled manner
with rigorous biologic testing for HIV before and after semen
washing to measure HIV seroconversion accurately. Individ-
ual studies did not calculate effect sizes, nor did they use sta-
tistical methods to adjust effect estimates. The risk of missing
data was very low overall, with HIV results before and after
exposure to washed semen available for 93.8% of women
and 97.2% of cycles included in this review. Thirty-nine
studies reported no loss to follow-up. Duration of follow-up
ranged from 3 months to 12 months, which are appropriate
lengths of follow-up to monitor for HIV seroconversion.
DISCUSSION
This is the most comprehensive systematic review and meta-
analysis to date evaluating the effect of semen washing on
HIV transmission among HIV-serodiscordant couples. We
found that semen washing provides a safe and effective
method for HIV-serodiscordant couples to become pregnant.
There were no instances of HIV seroconversion among HIV-
uninfected women inseminated with washed semen from
their HIV-infected partners. The estimated per-cycle HIV
transmission risk after semen washing is signiﬁcantly lower
than historical estimates of HIV transmission risk per act of
unprotected intercourse in both the overall population re-
viewed and the subgroup of men without viral suppression
at the time of semen washing. More than one-half of the cou-
ples in this review achieved a clinical pregnancy, and the rate
of spontaneous abortions reported was similar to general pop-
ulation estimates (63). There were no cases of vertical trans-
mission. HIV prevention programs that encourage couples
to attempt pregnancy with washed semen as an alternativeVOL. 105 NO. 3 / MARCH 2016
TABLE 2
Numbers of couples and cycles included in this review, and number
of HIV seroconversions.
Parameter Result
Initiated cycles of assisted reproduction
with washed semen
12,079
Completed cycles of assisted
reproduction with washed semen
11,915
Couples with at least one completed
cycle of assisted reproduction with
washed semen
4,257
Women with known HIV results after
exposure to washed semen
93.8% (3,994/4,257)
Completed cycles of assisted
reproduction among women with
known HIV results after exposure to
washed semen
97.2% (11,585/11,915)
Men known to be taking antiretroviral
therapy at time of semen washing
39.5% (1,685/4,257)
Men who were known to have not
achieved viral suppression at time of
semen washing (plasma testing)
27.7% (985/4,257)
Completed cycles of assisted
reproduction with the use of
washed semen among subgroup of
couples with a male partner who
was not virally suppressed
24.0% (2,863/11,915)
Number of HIV seroconversions (95% CI)
Per completed cycle of assisted
reproduction, overall
0/11,585 (0–0.0001)
Per woman with known HIV
outcome, overall
0/3,994 (0–0.0004)
Per completed cycle, among
subgroup of couples with a male
partner who was not virally
suppressed
0/2,863 (0–0.0006)
Per infant 0/1,026 (0–0.0029)
Note: CI ¼ conﬁdence interval; HIV ¼ human immunodeﬁciency virus.
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Fertility and Sterility®to intercourse without condoms may help to prevent the inci-
dence of sexual transmission of HIV (6).
Approximately one-half, 52.1%, of the men in studies
that reported viral loads of participants were not virally sup-
pressed at the time of semen washing. This number is an un-
derestimate of the true number of men who were virally
unsuppressed, because 12 of studies we reviewed did not
report on viral load and 19 did not report on antiretroviral
use. The absence of HIV transmission in this subgroup of
men without viral suppression suggests that semen washing
may be a safer and more effective reproductive method in set-
tings where men are unable or unwilling to initiate antiretro-
viral therapy, are nonadherent, or are not virally suppressed.
For example, in sub-Saharan Africa it is estimated that at
least one-third of individuals who have been taking antiretro-
virals for 12 months do not attain viral suppression (64).
Furthermore, up to 48% of men taking effective antiretroviral
therapy with undetectable viral load in blood plasma samples
have detectable virus in their semen (65, 66). Semen washing
may be relevant in such settings where men can access
antiretroviral therapy and are highly adherent to it but
remain at risk of transmitting HIV to their partners. Semen
washing may offer a safer alternative to intercourse withoutVOL. 105 NO. 3 / MARCH 2016condoms to prevent HIV transmission to the uninfected
female partner.
Some have argued that IVF and IVF/ICSI have better
fertility outcomes than IUI (31); however, the overall preg-
nancy success rates were similar between the methods in
the HIV-discordant couples reviewed. Additionally, some
have argued that IVF or IVF/ICSI poses less risk of HIV trans-
mission than IUI because it uses a single spermatozoon (67).
However, neither women nor newborns in the reviewed
studies acquired HIV after IUI with the use of washed semen.
Additionally, the vast majority of assisted reproduction cy-
cles performed used IUI. Although lower-cost IVF proce-
dures are being developed and evaluated, the method is
currently at least ten times costlier than IUI in most settings
(68, 69). Moreover, IVF is more invasive, carries some
surgical risk, and requires additional clinic and laboratory
capacity that may not exist in many low-resource settings.
Therefore, IUI with washed semen may offer an effective,
affordable, feasible, and safe strategy for preventing HIV
transmission among HIV-discordant couples desiring chil-
dren (70).
Traditionally, semen washing followed by assisted repro-
duction has been used to meet the needs of couples with infer-
tility or subfertility. A 2012 WHO study reported that
infertility affects one in four couples in developing countries
(71). That study estimated that infertility globally affected
48.5 million heterosexual stable couples that had been at-
tempting pregnancy forR5 years, of which 10 million lived
in sub-Saharan Africa, the region most affected by HIV
(71). Safer conception strategies in these areas must consider
not only the risk of HIV transmission but also underlying
infertility. Assisted reproduction with washed semen may
help both fertile and infertile couples achieve pregnancy,
while simultaneously reducing the risk of HIV transmission
to the woman and her newborn. However, the availability
of semen washing must be considered. Semen washing is
currently provided by only a limited number of fertility or
reproductive health centers worldwide. Establishing capacity
for semen washing in any part of the world will depend on the
availability of ﬁnancial and clinical resources and expertise
of clinical staff (70). Efforts to scale up capacity for semen
washing and the development of lower-cost procedures are
warranted, particularly in HIV endemic settings.
Despite a comprehensive search of the scientiﬁc litera-
ture, without language restrictions, limitations to include
only published studies, or sample size constraints, we did
not ﬁnd any published randomized control trials or cohort
studies with an internal comparison group to test the effect
of semen washing on HIV prevention in HIV-discordant cou-
ples. Without amatched and untreated comparison group, it is
difﬁcult to determine whether there would be a signiﬁcant
difference in the rate of HIV transmission between women
inseminated with washed semen compared with those who
were not. Given the absence of a direct comparison group,
studies have evaluated their results against historical esti-
mates of the overall risk of HIV transmission during unpro-
tected intercourse. This comparison has its limitations (72).
Furthermore, the lack of studies without a comparator group
affects the quality of our evidence. The GRADE approach to651
FIGURE 2
Proportion meta-analysis plot for human immunodeﬁciency virus (HIV) transmission probability and upper 95% conﬁdence interval (CI) after sperm
washing (A) per cycle and (B) per woman.
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ORIGINAL ARTICLE: ANDROLOGYassessing evidence quality by outcome denotes data from
observational studies with comparators as ‘‘low-quality evi-
dence’’ (23). Evidence quality can be graded down to very
low owing to a lack of internal comparators in the studies
evaluated. Because our included studies are single-arm obser-
vational trials, we assigned them a high risk of bias and
graded the evidence quality down to very low
(Supplemental Table 2, available online at www.fertstert.org).
The majority of studies included in this review did not
report on differences in semen quality between patients
with or without previous viral suppression. However, one
study by Nicopollous et al. (55) noted that semen parameters
were not signiﬁcantly different between men with detectable
and undetectable viral loads, despite signiﬁcantly lower CD4
counts among unsuppressed men. There is evidence in the
literature that although highly active antiretroviral treatment
impairs semen parameters, resulting in lower ejaculate vol-
ume and sperm with less motility (73), HIV parameters, such
as CD4 cell count, viral load, and duration of antiretroviral
therapy, are not signiﬁcantly correlated with semen quality
(74).
Studies included in this review did not report whether
there were signiﬁcant differences in pregnancy rates in the652different techniques (IUI, IVF, or IVF/ICSI) between patients
with and without viral suppression. However, one study by
Savasi et al. (49) calculated the rates of clinical pregnancy af-
ter IUI among participants taking antiretroviral therapy and
those not. The rate of clinical pregnancy per cycle in the group
taking antiretroviral medication (17.4%, 332/1,902) was not
signiﬁcantly different (P¼ .105) from the rate of clinical preg-
nancy in the group not taking antiretroviral medication (25%,
124/498). Because IUI and IVF procedures typically wash
sperm to prepare it for insemination regardless of the HIV sta-
tus of the patient, this review is unable to comment on rates of
birth outcomes after assisted reproduction without semen
washing.
A future direction of research may explore the utility of
conducting post-wash semen HIV testing. Very few (n ¼ 5)
of the studies included in this review reported on this method.
Additionally, no study compared rates of HIV transmission
after assisted reproduction with or without post-wash semen
HIV testing. Therefore, we are unable to comment on the util-
ity of conducting post-wash semen HIV testing before IUI or
IVF in this context.
This review has numerous strengths, including an exhaus-
tive search strategy, inclusion of 20 years of multinational andVOL. 105 NO. 3 / MARCH 2016
FIGURE 2 Continued
Zafer. Semen washing and HIV prevention. Fertil Steril 2016.
Fertility and Sterility®different-language studies, and the consistency of results
across the included studies. Additional strengths of the studies
included in this review include the use of serologic and viro-
logic testing of women before and after semen washing and
extremely high rates of participant retention. Finally, a major
strength of this review is its large sample size; this review in-
cludes 11,585 completed cycles of assisted reproduction with
known HIV outcomes and 2,863 cycles in which HIV-
infected men had not attained viral suppression.
CONCLUSION
The absence of HIV seroconversion in the reviewed studies
suggests that semen washing prevents HIV transmission in
HIV-discordant couples attempting pregnancy where the
man is infected. There is a lack of studies on semen washing
from low-income and lower-middle income countries,
including countries in sub-Saharan Africa with a high HIV
prevalence. Efforts to develop lower-cost semen washing
and assisted reproduction technologies that can be used in
settings with fewer resources are therefore warranted. Inte-
gration of semen washing into HIV prevention protocols
may help to curb the incidence of sexual HIV transmission.VOL. 105 NO. 3 / MARCH 2016REFERENCES
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SUPPLEMENTAL TABLE 1
Age of participants and pregnancy outcomes.
Variable IUI IVF or IVF/ICSI Overall
Age range in y
Men 31–38 29–58 29–58
Women 29–38 30–40 29–40
Pregnancy outcomes, % (95% CI), (n)
Proportion of initiated cycles of assisted
reproduction with the use of semen
washing that resulted in pregnancy
17.9 (17.0–18.9), (1,184/6,599) 32.3 (30.0–34.6), (545/1,687) 19.9 (19.1–20.6), (2,331/11,742)
Proportion of couples that achieved
pregnancy
56.4 (54.2–58.5), (1,162/2,062) 58.1 (55.0–61.1), (593/1,020) 56.3 (54.8–57.8), (2,357/4,184)
Proportion of pregnancies ending in
spontaneous abortion (per couple)
15.5 (13,4–17.7), (182/1,177) 17.7 (13.9–22.0), (65/367) 17.0 (15.4–18.6), (376/2,215)
Note: The number of pregnancies, couples, cycles, and spontaneous abortions for IUI, IVF, or IVF/ICSI may not add up to the number of total events observed. This is because not all studies reported
pregnancy outcomes and not all studies provided data disaggregated by IUI, IVF, or IVF/ICSI. ICSI ¼ intracytoplasmic sperm injection; IUI ¼ Intrauterine insemination; IVF ¼ In vitro fertilization.
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SUPPLEMENTAL TABLE 2
GRADE evidence quality assessment: Is semen washing effective in preventing HIV seroconversion in women and their infants? (observational
studies; n[ 40)
HIV seroconversion Bias risk Inconsistency Indirectness Imprecision Evidence quality
Per completed cycle of assisted
reproduction, overall
Very serious riska No serious risk No serious riskb No serious riskc Very low
Per woman with known HIV outcome,
overall
Very serious riska No serious risk No serious riskb No serious riskc Very low
Per completed cycle, among subgroup of
couples with a male partner who was
not virally suppressed
Very serious riska No serious risk No serious riskb No serious riskc Very low
Per infant Very serious riska No serious risk No serious riskb No serious riskc Very low
Note: HIV ¼ human immunodeﬁciency virus.
a Single-arm studies, no internal comparator.
b Without a comparator, not direct, but this problem is covered under bias risk.
c No events, but owing to lack of comparator this problem is covered under bias risk.
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